...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials
【24h】

Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials

机译：肺癌患者潜在药代动力学药物 - 药物相互作用的患病率和意义：临床试验的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The overall prevalence of potential drug-drug interactions (DDIs) among patients with lung cancer is unknown. Objective The objective of this study was to determine the prevalence of potential DDIs and major DDIs among individuals newly diagnosed with lung cancer in a national cohort. Patients and Methods We performed a retrospective cross-sectional study of adult patients in the United States Veterans' Affairs (VA) medical system diagnosed with lung cancer between 2003 and 2016. The primary endpoint was the prevalence of prescriptions for medications associated with any potential DDIs during the 3 months leading up to and including the date of lung cancer diagnosis. The secondary endpoint was the prevalence of prescriptions associated with major DDIs during the same time period. Results Overall, 280,068 patients were included in the study; 55.9% of patients were prescribed medications associated with potential DDIs, while 5.3% received prescriptions for medications associated with major DDIs. Among the 20 most commonly prescribed drugs associated with potential DDIs, only two were associated with major DDIs. Conclusion Medications with potential DDIs are prescribed to the majority of patients with lung cancer; however, only about 5% of patients are prescribed medications with major DDIs that might be prohibited in certain clinical trials.
机译：None

著录项

  • 来源
    《Clinical drug investigation》 |2021年第2期|共7页
  • 作者

    Rashdan Sawsan; Yang Hui; Le Tri; Selby Christopher; Gerber David E.; Alvarez Carlos A.;

  • 作者单位

    Univ Texas Southwestern Med Ctr Dallas Harold C Simmons Comprehens Canc Ctr Dallas TX 75390 USA;

    Texas Tech Univ Hlth Sci Ctr Pharm Practice 5920 Forest Pk Rd Suite 400 Dallas TX 75235 USA;

    Univ Texas Southwestern Internal Med Dallas TX USA;

    Texas Tech Univ Hlth Sci Ctr Pharm Practice 5920 Forest Pk Rd Suite 400 Dallas TX 75235 USA;

    Univ Texas Southwestern Med Ctr Dallas Harold C Simmons Comprehens Canc Ctr Dallas TX 75390 USA;

    Texas Tech Univ Hlth Sci Ctr Pharm Practice 5920 Forest Pk Rd Suite 400 Dallas TX 75235 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号